Navigation Links
Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:12/21/2011

CARSON CITY, Nev., Dec. 21, 2011 /PRNewswire/ -- Denali Concrete Management Inc. (OTCBB: DCMG) announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel. The randomized, double-masked clinical trial will include 231 patients who will be randomized to receive 2 doses of CF101 and Placebo, for a period of 24 weeks.  The primary efficacy endpoint will be complete clearing of corneal staining.

The population suffering from Dry Eye Syndrome is estimated at 49 million people in the seven major markets and is characterized by eye irritation symptoms, blurred and fluctuating vision, tear film instability, increased tear osmolarity and ocular surface epithelial disease. People with Dry Eye Syndrome experience constant ocular discomfort and a decrease in visual function; in severe cases, Dry Eye Syndrome may result in deterioration of vision.

Dr. Pnina Fishman, the Company's interim CEO stated, "We are very pleased with the initiation of enrollment to the Dry Eye Syndrome phase 3 study. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral drug for the treatment of Dry Eye Syndrome."

In addition, the Company announces today that by action of the Board of Directors and the shareholders, it has changed its name to OphthaliX Inc.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications including Dry Eye Syndrome (Phase 3), Glaucoma (Phase 2) and Uveitis. CF101 is also developed for the trea
'/>"/>

SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
2. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
5. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. Cellectar Expands Clinical Management Team
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
10. Lilly Receives NCQA Design Certification for Depression Care Management Program
11. Micromet Announces Changes in Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... 2015  CCS Medical ("CCS"), one of the ... patients with chronic conditions, has named Rodney ... effective March 23.  Mr. Carson joins CCS from ... was President of Operations. Prior ... Vice President of Operations at NationsHealth, (n/k/a Convey ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8CCS Medical Team Hires Industry Operator Rodney Carson as CEO 2
... SOMERSET, N.J., Jan. 30 Alfacell Corporation,(Nasdaq: ACEL ... occurred in the Phase IIIb clinical trial of its ... malignant,mesothelioma. Enrollment in the ONCONASE Phase IIIb clinical trial ... patients were enrolled in the,trial., In accordance with ...
... Breast ... Cancer Patients, EVERGREEN PARK, ... Centers in Evergreen Park, Illinois, near Chicago,( http://www.PursuingPainFreeCancer.org/breastcancer ), has announced ... for the,treatment of early stage breast cancer. The study involves the ...
Cached Medicine Technology:Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program 2Breast Cancer Treatment Is Reduced to One Week 2
(Date:3/27/2015)... While deep learning was the topic of many conversations ... the CEO of one start-up spoke passionately about using fast ... beyond the generally-agreed ceiling of 120 years. , Insilico Medicine, ... 12 companies recognized as the hottest GPU-powered startups in the ... Emerging Companies Summit have business models focused on self-driving ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and ... information on and analysis of the healthcare, regulatory and ... US in 2013 amounted to 316.1 million, having grown ... from 2008. The country’s increasingly elderly population and corresponding ... to boost the growth of the pharmaceutical market, which ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
(Date:3/27/2015)... Bellevue, WA (PRWEB) March 27, 2015 ... it can be hard to know where to begin. ... an experienced Seattle trucking accident attorney, offers accident victims ... financial, and legal assistance to ensure their personal injury ... eBook begins by describing the first actions that should ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , KENILWORTH, N.J., Aug. 11 ... an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus ... formulations of CLARINEX(R) (desloratadine). , , ... filed and consolidated since 2006 in the U.S. District Court ...
... , Survey seeks feedback from public to help ... CHICAGO, Aug. 11 Participate in the American Dental Association (ADA) ... and become eligible to win a $150 Amazon.com gift certificate and, at the ... ADA.org provides news and information on hundreds of dental topics, ranging from ...
... , MOUNTAIN VIEW, Calif., Aug. 11 VIVUS, ... and commercialization of novel therapeutic products, today reported its financial results for the ... Second Quarter Results , , Net loss ... as compared to net income of $3.6 million, or $0.06 per share, for ...
... , , VERNON HILLS, ... provider of vascular access management services, today announced the launch ... integrated network for physicians to act as one to deliver ... new program has the potential to ultimately save money for ...
... , , SAN BERNARDINO, Calif., Aug. 11 ... food junkies, the all new comic book superhero, Super Nutricia, created by Inland ... children. This is the first ever female superhero from IEHP,s squad of masked ... (Photo: http://www.newscom.com/cgi-bin/prnh/2 0 090811/DC6 0 ...
... newborns experiencing a fatal lack of oxygen, study finds , ... there,s been a nearly 40 percent drop in the risk ... infants in Scotland, new research has found. , The major ... of deaths caused by a lack of oxygen for the ...
Cached Medicine News:Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 2Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 3Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 3Health News:VIVUS Reports Second Quarter 2009 Financial Results 4Health News:VIVUS Reports Second Quarter 2009 Financial Results 5Health News:VIVUS Reports Second Quarter 2009 Financial Results 6Health News:VIVUS Reports Second Quarter 2009 Financial Results 7Health News:Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 3Health News:Delivery-Related Infant Deaths Decline in Scotland 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: